Jade Biosciences (NASDAQ: JBIO) prices $150M common stock sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Jade Biosciences, Inc. entered into an underwriting agreement for a public offering of 10,000,000 shares of common stock at $15.00 per share, with underwriters purchasing at $14.10 per share. Jade expects gross proceeds of $150.0 million and net proceeds of approximately $140.3 million.
The company granted underwriters a 30-day option to buy up to an additional 1,500,000 shares at the public price, which would raise expected net proceeds to about $161.5 million if exercised in full. The offering, conducted under an effective Form S-3 shelf registration, is expected to close on June 5, 2026, and Jade plans to use net proceeds to fund clinical and preclinical programs, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Positive
- None.
Negative
- None.
Insights
Jade raises up to ~$161.5M via a common stock offering.
Jade Biosciences is issuing 10,000,000 common shares at $15.00, with underwriters paying $14.10. This primary equity raise should generate about $140.3M in net proceeds, or $161.5M if the 1,500,000-share over-allotment option is fully exercised.
The capital is earmarked for clinical trials, preclinical studies, manufacturing, broader R&D, capital expenditures, working capital and other corporate uses. As a clinical-stage company without product revenue, access to this funding can be important for advancing programs like JADE101, JADE201 and JADE301.
The transaction uses an existing Form S-3 shelf and is expected to close on June 5, 2026, subject to customary conditions. Actual impact for shareholders will depend on the final take-up of the 30-day option and future progress of Jade’s autoimmune pipeline.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares offered: 10,000,000 shares
Public offering price: $15.00 per share
Underwriters’ purchase price: $14.10 per share
+5 more
8 metrics
Shares offered
10,000,000 shares
Common stock in underwritten public offering
Public offering price
$15.00 per share
Price to the public for common stock
Underwriters’ purchase price
$14.10 per share
Price paid by underwriters under the agreement
Gross proceeds
$150.0 million
Expected gross proceeds from 10,000,000 shares, excluding option
Net proceeds base
$140.3 million
Expected net proceeds after fees and expenses, excluding option
Net proceeds with option
$161.5 million
Expected net proceeds if 1,500,000-share option exercised in full
Over-allotment shares
1,500,000 shares
30-day option for underwriters to purchase additional shares
Shelf registration
Form S-3 No. 333-295662
Registration statement for this offering
Key Terms
underwriting agreement, shelf registration statement, prospectus supplement, pre-funded warrants, +2 more
6 terms
underwriting agreement financial
"Jade Biosciences, Inc. (“Jade” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC..."
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
shelf registration statement regulatory
"The offering is being made pursuant to the Company’s shelf registration statement on Form S-3..."
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"a prospectus supplement and the accompanying prospectus filed with the SEC on June 3, 2026 pursuant to Rule 424(b)..."
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
pre-funded warrants financial
"common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock..."
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
forward-looking statements regulatory
"Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws..."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
book-running managers financial
"Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the offering."
Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.
FAQ
What is Jade Biosciences (JBIO) raising through its June 2026 stock offering?
Jade Biosciences is raising capital by selling 10,000,000 shares of common stock at $15.00 per share. This primary offering is expected to generate gross proceeds of $150.0 million before underwriting discounts, commissions, and expenses, supporting its autoimmune disease drug development programs.
How much will Jade Biosciences (JBIO) receive in net proceeds from the offering?
Jade expects net proceeds of approximately $140.3 million from the 10,000,000-share offering. If underwriters fully exercise their 30-day option to buy 1,500,000 additional shares, net proceeds are expected to increase to about $161.5 million after underwriting discounts and estimated offering expenses.
Does Jade Biosciences’ June 2026 deal include an over-allotment option for underwriters?
Yes. Jade granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock. These additional shares would be sold at the public offering price, less underwriting discounts and commissions, potentially increasing total net proceeds beyond $140.3 million.
How does Jade Biosciences plan to use the proceeds from this offering?
Jade plans to use net proceeds, alongside existing cash, to fund clinical trials, preclinical studies, and manufacturing for its programs. Additional proceeds will support broader research and development activities, capital expenditures, working capital needs, and other general corporate purposes across its autoimmune pipeline.
When is Jade Biosciences’ June 2026 stock offering expected to close?
The offering is expected to close on June 5, 2026, provided customary closing conditions are satisfied. Closing will follow execution of the underwriting agreement and is conducted under Jade’s effective Form S-3 shelf registration and related prospectus supplement filed with the SEC.